Predictions
MacroGenics Inc.
Start price
Target price
Perf. (%)
€16.79
19.09.21
19.09.21
-
19.09.22
19.09.22
-79.51%
20.09.22
20.09.22
Probably not worthwhile Investment
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€25.05
19.09.21
19.09.21
-
19.09.22
19.09.22
-85.23%
20.09.22
20.09.22
Growths faster than the competition
Risky Investment
Celyad SA ADR
Start price
Target price
Perf. (%)
€3.58
19.09.21
19.09.21
-
19.09.22
19.09.22
-53.35%
20.09.22
20.09.22
Probably not worthwhile Investment
Burcon Nutrascience Corp.
Start price
Target price
Perf. (%)
€1.53
19.09.21
19.09.21
-
19.09.22
19.09.22
-75.74%
20.09.22
20.09.22
Probably not worthwhile Investment
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€5.30
18.09.21
18.09.21
-
18.09.22
18.09.22
-63.56%
19.09.22
19.09.22
Risky Investment
High risks for its business
Dependend from few customers or products
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€5.20
18.09.21
18.09.21
€10.00
31.12.23
31.12.23
-79.42%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
PDS Biotechnology Corp.
Start price
Target price
Perf. (%)
€12.54
18.09.21
18.09.21
€20.00
31.12.23
31.12.23
-52.05%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Spectrum Pharmaceuticals
Start price
Target price
Perf. (%)
€2.60
18.09.21
18.09.21
€5.00
31.12.23
31.12.23
-62.67%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€14.20
18.09.21
18.09.21
€40.00
31.12.23
31.12.23
61.97%
16.12.21
16.12.21
Could be very worthwhile Investment >20% year
Innate Pharma
Start price
Target price
Perf. (%)
€6.61
18.09.21
18.09.21
€3.00
18.09.22
18.09.22
-22.01%
02.10.21
02.10.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€5.20
18.09.21
18.09.21
€2.00
18.09.22
18.09.22
-22.69%
02.10.21
02.10.21
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
First Wave BioPharma Inc.
Start price
Target price
Perf. (%)
€675.52
18.09.21
18.09.21
€209.79
18.09.22
18.09.22
-25.47%
02.10.21
02.10.21
Low dividend yield expected
Bad rating
ROE lower than 10% per year
Sustainability is little important
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€3.00
17.09.21
17.09.21
-
17.09.22
17.09.22
73.33%
19.09.21
19.09.21
Risky Investment
Forte Biosciences Inc.
Start price
Target price
Perf. (%)
€2.94
15.09.21
15.09.21
-
15.09.22
15.09.22
0.00%
19.09.21
19.09.21
Risky Investment
Nuvo Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€0.94
15.09.21
15.09.21
€1.20
15.09.22
15.09.22
11.23%
05.12.21
05.12.21
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Higher risks for its business
Below average Marketposition
BELLUS Health Inc.
Start price
Target price
Perf. (%)
€4.89
15.09.21
15.09.21
€5.85
15.09.22
15.09.22
1.27%
22.10.21
22.10.21
Could be very worthwhile Investment >20% year
Future proof or reliable business model
Higher risks for its business
GSK plc ADR
Start price
Target price
Perf. (%)
€41.25
15.09.21
15.09.21
€43.75
15.09.22
15.09.22
-16.61%
15.08.22
15.08.22
Could be worthwhile Investment >10% per year
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€4.48
14.09.21
14.09.21
-
14.09.22
14.09.22
-4.46%
19.09.21
19.09.21
Risky Investment
Eckert & Ziegler BEBIG SA
Start price
Target price
Perf. (%)
-
14.09.21
14.09.21
€137.00
14.09.22
14.09.22
-
10.07.22
10.07.22
Could be worthwhile Investment >10% per year
Forte Biosciences Inc.
Start price
Target price
Perf. (%)
€3.50
14.09.21
14.09.21
-
14.09.22
14.09.22
-30.29%
05.10.21
05.10.21
Innovative
Valneva SE
Start price
Target price
Perf. (%)
€11.82
14.09.21
14.09.21
€30.00
14.09.22
14.09.22
-29.36%
15.09.22
15.09.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Future proof or reliable business model
Standard Investments for future growth
Valneva SE
Start price
Target price
Perf. (%)
€11.84
13.09.21
13.09.21
-
13.09.22
13.09.22
139.19%
29.11.21
29.11.21
Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€5.30
13.09.21
13.09.21
-
13.09.22
13.09.22
8.49%
19.09.21
19.09.21
Risky Investment
Valneva SE
Start price
Target price
Perf. (%)
€12.34
13.09.21
13.09.21
€9.00
13.09.22
13.09.22
100.65%
16.12.21
16.12.21
Could be very worthwhile Investment >20% year